Treatment of Behçet's Syndrome with Acute Deep Vein Thrombosis
Behçet's syndrome (BS) is a systemic vasculitis that can involve major venous structures. When acute deep vein thrombosis arises in this context, the thrombotic event reflects the underlying inflammatory vasculopathy and requires a targeted protocol addressing both dimensions.
Clinical scenario: Behçet's syndrome presenting with acute deep vein thrombosis — a vascular complication in which immunosuppressive management and careful assessment of thrombotic risk are both central to treatment planning.
Management of this presentation involves immunosuppressive therapy directed at the inflammatory mechanisms driving vascular involvement. A biologic strategy targeting tumour necrosis factor may be part of the approach in appropriate patients.
Further detail on the full regimen — including when and how additional interventions may apply — is in the complete protocol →
References
DOI: 10.1136/annrheumdis-2018-213225
- For the management of acute deep vein thrombosis in BS, glucocorticoids and immunosuppressives such as azathioprine, cyclophosphamide or cyclosporine-A are recommended.
- Monoclonal anti-TNF antibodies could be considered in refractory patients.
- Anticoagulants may be added, provided the risk of bleeding in general is low and coexistent pulmonary artery aneurysms are ruled out.
View source ↗